Amgen (AMGN) news
Recent news
FTC files amicus brief in Amgen antitrust case
The Federal Trade Commission (FTC) has filed an amicus brief in an ongoing antitrust case involving Amgen Inc., supporting the legal arguments of CareFirst of Maryland, Inc. The case centers on allegations that Amgen engaged in anticompetitive conduct by extending its monopoly over the drug Enbrel…
AInvest Wire · 7d agoAmgen Inc: Argus Research raises target price to $460
Amgen Inc. (AMGN) has recently seen an upward adjustment in its price target from Argus Research, which raised its forecast to $460 from $450, maintaining a "buy" rating for the stock. This move reflects a positive outlook on the biotechnology company's performance and potential for growth. As of…
AInvest Wire · Aug 19, 2026Dow Jones unofficially closes down 107.39 points, or 0.20%, at 53,352.39
On August 18, 2026, the Dow Jones Industrial Average (DJIA) closed unofficially down 107.39 points , or 0.20%, at 53,352.39. The decline was driven by losses in key components, including Salesforce (-2.25%), Cisco Systems (-1.67%), and Amgen (-1.28%). These declines contributed to the overall…
AInvest Wire · Aug 18, 2026Amgen Inc: Mizuho raises target price to $352 from $303
Mizuho Securities has raised its price target for Amgen Inc. (NASDAQ:AMGN) to $352 from $303, while maintaining a Neutral rating on the stock, according to a recent research note . The adjustment reflects the firm’s updated medium-term sales outlook for the biotechnology company, driven by key…
AInvest Wire · Aug 18, 2026AstraZeneca: officially launched Tezspire in China - company statement
AstraZeneca has officially launched Tezspire (tezepelumab) in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, following regulatory approvals from the NMPA . This marks a significant milestone for the company, as Tezspire is the first biologic in China…
AInvest Wire · Aug 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.